Tong Z - Search Results

1

In vitro inhibition of human nucleoside transporters and uptake of azacitidine by an isocitrate dehydrogenase-2 inhibitor enasidenib and its metabolite AGI-16903.

Tong Z, Yerramilli U, Yao S, Young JD, Hoffmann M, Surapaneni S. Tong Z, et al. Xenobiotica. 2019 Oct;49(10):1229-1236. doi: 10.1080/00498254.2018.1539783. Epub 2018 Nov 29. Xenobiotica. 2019. PMID: 30394160

2

Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.

Damaraju VL, Mowles D, Yao S, Ng A, Young JD, Cass CE, Tong Z. Damaraju VL, et al. Among authors: tong z. Nucleosides Nucleotides Nucleic Acids. 2012;31(3):236-55. doi: 10.1080/15257770.2011.652330. Nucleosides Nucleotides Nucleic Acids. 2012. PMID: 22356238

3

Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans.

Tong Z, Atsriku C, Yerramilli U, Wang X, Nissel J, Li Y, Surapaneni S. Tong Z, et al. Xenobiotica. 2019 Jan;49(1):43-53. doi: 10.1080/00498254.2017.1413718. Epub 2017 Dec 19. Xenobiotica. 2019. PMID: 29206565

4

Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans.

Tong Z, Atsriku C, Yerramilli U, Wang X, Li Y, Reyes J, Fan B, Yang H, Hoffmann M, Surapaneni S. Tong Z, et al. Xenobiotica. 2019 Feb;49(2):200-210. doi: 10.1080/00498254.2018.1425511. Epub 2018 Jan 22. Xenobiotica. 2019. PMID: 29320949

5

Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase.

Tong Z, Gaudy A, Tatosian D, Ramirez-Valle F, Liu H, Chen J, Hoffmann M, Surapaneni S. Tong Z, et al. Xenobiotica. 2021 Dec;51(12):1416-1426. doi: 10.1080/00498254.2022.2027553. Epub 2022 Jan 13. Xenobiotica. 2021. PMID: 35000550

6

The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions.

Tong Z, Yerramilli U, Surapaneni S, Kumar G. Tong Z, et al. Cancer Chemother Pharmacol. 2014 Apr;73(4):869-74. doi: 10.1007/s00280-014-2415-y. Epub 2014 Mar 14. Cancer Chemother Pharmacol. 2014. PMID: 24627218

7

Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase.

Tong Z, Narayanan R, Atsriku C, Nissel J, Li Y, Liu H, Wang X, Surapaneni S. Tong Z, et al. Xenobiotica. 2019 Jan;49(1):54-70. doi: 10.1080/00498254.2018.1424377. Epub 2018 Jan 17. Xenobiotica. 2019. PMID: 29297772

8

Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction.

Xue YJ, Hoffmann M, Tong Z, Wu XI, Vallejo M, Melo B, Ye Y, Thomas M, Liu Y, Weiss D, Surapaneni S. Xue YJ, et al. Among authors: tong z. Bioanalysis. 2016 Feb;8(3):215-28. doi: 10.4155/bio.15.241. Epub 2016 Jan 25. Bioanalysis. 2016. PMID: 26805594

9

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects.

Li Y, Liu L, Gomez D, Chen J, Tong Z, Palmisano M, Zhou S. Li Y, et al. Among authors: tong z. Pharmacol Res Perspect. 2018 Oct 23;6(6):e00436. doi: 10.1002/prp2.436. eCollection 2018 Dec. Pharmacol Res Perspect. 2018. PMID: 30386625 Free PMC article. Clinical Trial.

10

Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.

Cheng Y, Wang X, Tong Z, Reyes J, Carayannopoulos L, Zhou S, Li Y. Cheng Y, et al. Among authors: tong z. J Clin Pharmacol. 2022 Apr;62(4):494-504. doi: 10.1002/jcph.1979. Epub 2021 Oct 27. J Clin Pharmacol. 2022. PMID: 34617279

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,796 results

Search Page

Filters